Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02691312 · ClinicalTrials.gov registry record
Pediatric Type 1 Diabetes and Retinopathy
A clinical trial of Diabetic Retinopathy, sponsored by University of Florida.
- Completed
- Registry status
- 500
- Enrollment target
- 3
- Study locations
NCT02691312: Completed study of Diabetic Retinopathy, sponsored by University of Florida.
NCT02691312 is a study of Diabetic Retinopathy that has completed, run by University of Florida. The registered enrollment target is 500 participants, below the 1,668-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (70% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02691312, a study of Diabetic Retinopathy, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- 500 participants
- Enrollment target
- 3
- Study locations
Study Summary
Diabetic retinopathy (DR) causes more new cases of blindness among young adults than any other disease. More than 90% of individuals with type 1 diabetes (T1D) will have some form of DR by 20 years after their diagnosis. DR is associated with long-term hyperglycemia and blood glucose variability, which induces vascular endothelial dysfunction and destruction in the retina, eventual retinal ischemia, and in the end, widespread neovascularization of the retina and optic disk. When these fragile vessels bleed, they can cause vitreous hemorrhage and loss of vision. Eventually the friable vessels fibrose and can result in retinal detachment or further retinal ischemia. Major risk factors for the development of diabetic retinopathy are time since diagnosis, age at diagnosis, and severity of hyperglycemia. Retinopathy most commonly occurs at least three years after diagnosis and most cases are diagnosed more than five years after the onset of T1D. Current guidelines from the American Diabetes Association (ADA) and American Academy of Ophthalmology (AAO) recommend that patients with T1D undergo an initial comprehensive dilated fundoscopic evaluation once the individual has had diabetes for 3-5 years and has either reached puberty or 10 years of age, whichever is earlier. These patients should receive a yearly exam thereafter, or every two years based upon the recommendation of an eye care professional. However, the prevalence of retinopathy in children is unknown and adherence to these guidelines, especially in youth, has proven difficult. Thus, it is important to make these guidelines more evidence based, as retinopathy is often asymptomatic until vision loss occurs. The first step in this process is the determination of the prevalence of retinopathy in a general population of youth with diabetes. This should be followed by determining which children are most at risk, so the guidelines can provide realistic and pertinent guidance to practitioners.
Primary Outcome
Using a CenterVue Digital Retinography System (DRS) the participants with a positive or inconclusive screen will be called with the results and recommended to undergo a dilated eye examination by a skilled ophthalmologist. The results from the ophthalmologist will be compared to the DRS results.
Conditions Studied
Interventions
- DEVICE Digital Retinography System
Study Locations (3)
Florida
- Florida Diabetes Camps - De Leon Springs
- Pediatrics Endocrinology/Diabetes at UF Health Medical Plaza and Children's Medical Services Building - Gainesville
- Children With Diabetes Friends For Life Conference - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2016-07 |
| Est. Completion | 2018-12-27 |
What the finished NCT02691312 record still lists
NCT02691312 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 1,668-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Diabetic Retinopathy appearing as the primary indexed condition, and to 1 intervention - of which Digital Retinography System is the first listed.
NCT02691312 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02691312 about?
NCT02691312 is a clinical study titled "Pediatric Type 1 Diabetes and Retinopathy". Diabetic retinopathy (DR) causes more new cases of blindness among young adults than any other disease. More than 90% of individuals with type 1 diabetes (T1D) will have some form of DR by 20 years after their diagnosis. DR is associated with long-term hyperglycemia and blood glucose variability, wh...
What is the current status of trial NCT02691312?
This trial is currently completed. The enrollment target is 500 participants. The study started on 2016-07. Estimated completion is 2018-12-27.
What conditions does trial NCT02691312 study?
This clinical trial studies the following conditions: Diabetic Retinopathy.
What interventions are being tested in trial NCT02691312?
The interventions under investigation include: Digital Retinography System (DEVICE).
Who is sponsoring clinical trial NCT02691312?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02691312 being conducted?
This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02691312's enrollment target sits among peer trials
500 17th of 57 higher than 41 of 57 other Diabetic Retinopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Retinopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fenofibrate for Prevention of DR Worsening
RECRUITING · Phase 3
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
RECRUITING
-
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
RECRUITING · NA
-
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
RECRUITING · Phase 2
-
Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia